BIIB - Biogen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
319.44
+2.71 (+0.86%)
At close: 4:00PM EST

319.40 -0.04 (-0.01%)
After hours: 6:04PM EST

Stock chart is not supported by your current browser
Previous Close316.73
Open317.94
Bid310.53 x 1000
Ask323.50 x 900
Day's Range310.99 - 321.11
52 Week Range249.17 - 388.67
Volume965,813
Avg. Volume1,271,056
Market Cap64.362B
Beta (3Y Monthly)1.99
PE Ratio (TTM)20.88
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101
    Zacks6 days ago

    FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101

    The FDA accepts Novartis' (NVS) BLA for AVXS-101 and grants Priority Review to the same.

  • AbbVie Presents Long-Term Data on Cancer Drugs at ASH 2018
    Zacks7 days ago

    AbbVie Presents Long-Term Data on Cancer Drugs at ASH 2018

    AbbVie (ABBV) presents positive long-term data from two separate clinical studies evaluating its cancer drugs, Venclexta and Imbruvica, in leukemia patients at the American Society of Hematology (ASH) annual meeting.

  • Pfizer Stock Edges Into Buy Zone On AbbVie Deal For Humira Biosimilar
    Investor's Business Daily10 days ago

    Pfizer Stock Edges Into Buy Zone On AbbVie Deal For Humira Biosimilar

    Pfizer on Friday joined a slew of pharmaceutical stocks with licensing deals to launch a Humira biosimilar under a deal with AbbVie.

  • How Much Upside Wall Street Sees in Sangamo Stock
    Market Realist10 days ago

    How Much Upside Wall Street Sees in Sangamo Stock

    In November, of the total eight analysts covering Sangamo Therapeutics (SGMO), five have given the stock a “buy” or higher rating and three analysts have given it a “hold” rating. The mean rating for Sangamo Therapeutics stock is 2.0 with a target price of $22.71, implying an upside potential of 90.5% over the closing price of $11.92 on November 29.

  • Taking Stock of Sangamo’s Financial Performance
    Market Realist10 days ago

    Taking Stock of Sangamo’s Financial Performance

    Sangamo Therapeutics (SGMO) focuses on developing and bringing to market novel genomic therapies. Its genome editing and gene regulation technology platform is enabled by engineering transcription factors called zinc finger DNA-binding proteins, which can increase or decrease gene expression or gene regulation.

  • Analyzing Sangamo Therapeutics’ Operational Performance
    Market Realist10 days ago

    Analyzing Sangamo Therapeutics’ Operational Performance

    Sangamo Therapeutics (SGMO) incurred general and administrative expenses of $10.99 million in the third quarter of 2018, compared with $6.42 million in the third quarter of 2017. The fiscal 2018 research and development expenses for peers Amgen (AMGN), Biogen (BIIB), and Gilead Sciences (GILD) are expected at $3.52 billion, $2.48 billion, and $3.71 billion, respectively. Sangamo Therapeutics’ net interest and other income grew from $681,000 in the third quarter of 2017 to $3.4 million in the latest quarter.

  • How To Trade Growth Stocks: Why Biogen Fell Below Its Buy Point On Breakout Day But Still Won Big
    Investor's Business Daily11 days ago

    How To Trade Growth Stocks: Why Biogen Fell Below Its Buy Point On Breakout Day But Still Won Big

    Should you immediately sell a stock when it breaks out but closes beneath the proper buy point? Not always. Here are some tips on when to sit tight and when to bail early.

  • Teva's Rituxan Biosimilar Gets FDA Nod in Non-Hodgkin Lymphoma
    Zacks11 days ago

    Teva's Rituxan Biosimilar Gets FDA Nod in Non-Hodgkin Lymphoma

    Teva (TEVA) and partner Celltrion get FDA nod for approval of their biosimilar to Roche's Rituxan in three Non-Hodgkin's lymphoma indications.

  • GuruFocus.com13 days ago

    Health Care Stocks May Be Safe Haven in Event of Market Downturn

    It's generally accepted that health care is considered one of the top defensive sectors. Warning! GuruFocus has detected 6 Warning Signs with UNH. One large-cap stock that stands out is UnitedHealth Group (UNH).

  • See what the IHS Markit Score report has to say about Biogen Inc.
    Markit13 days ago

    See what the IHS Markit Score report has to say about Biogen Inc.

    Biogen Inc NASDAQ/NGS:BIIB

  • Hedge Funds Are Crazy About Biogen Inc. (NASDAQ:BIIB)
    Insider Monkey14 days ago

    Hedge Funds Are Crazy About Biogen Inc. (NASDAQ:BIIB)

    It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren’t usually symmetrically distributed and index […]

  • United Therapeutics: A Financial Overview in November
    Market Realist14 days ago

    United Therapeutics: A Financial Overview in November

    United Therapeutics (UTHR) generated net revenues of $412.7 million in the third quarter—compared to $445.5 million during the third quarter of 2017, which reflected a decline of ~7% YoY (year-over-year). United Therapeutics’ net revenues during the first nine months of 2018 were $1.25 billion—compared to $1.26 billion during the same period in 2017, which reflected a decline of 1% YoY.

  • United Therapeutics: Recent Developments and Analysts’ Ratings
    Market Realist14 days ago

    United Therapeutics: Recent Developments and Analysts’ Ratings

    On November 15, United Therapeutics (UTHR) entered into a global license agreement with Arena Pharmaceuticals (ARNA). According to the agreement, Arena Pharmaceuticals will provide United Therapeutics exclusive worldwide rights to develop, manufacture, and commercialize its investigational drug, ralinepag, to treat individuals with pulmonary arterial hypertension. Currently, ralinepag is in its Phase 3 clinical stage.

  • Reuters17 days ago

    US benefits manager baulks after Novartis values gene therapy at $4-5 mln

    Just weeks after Novartis floated the idea that $4-5 million was fair value for its new gene therapy against a deadly neuromuscular disease, a major benefits manager is pushing back. Among the first to react was pharmacy benefits manager Express Scripts, which helps U.S. employers manage workers' prescription costs. Its chief medical officer, Steve Miller, told Reuters he "loves the science" behind Novartis's therapy, a potential cure for newborns who are diagnosed early.

  • Why Biogen Inc (NASDAQ:BIIB) Looks Like A Quality Company
    Simply Wall St.17 days ago

    Why Biogen Inc (NASDAQ:BIIB) Looks Like A Quality Company

    While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it Read More...

  • Reuters18 days ago

    U.S. benefits manager baulks after Novartis values gene therapy at $4-5 million

    Just weeks after Novartis floated the idea that $4-5 million was fair value for its new gene therapy against a deadly neuromuscular disease, a major benefits manager is pushing back. The Swiss drugmaker's assessment of AVXS-101's value for treating spinal muscular atrophy (SMA) has put the company front-and-centre in the debate over what "super drugs", for rare diseases afflicting relatively few patients, are really worth. Among the first to react was pharmacy benefits manager Express Scripts, which helps U.S. employers manage workers' prescription costs.

  • Why Is Biogen (BIIB) Up 4.5% Since Last Earnings Report?
    Zacks18 days ago

    Why Is Biogen (BIIB) Up 4.5% Since Last Earnings Report?

    Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Drug prices may be rising, but you can buy biotech stocks at rock-bottom levels
    MarketWatch26 days ago

    Drug prices may be rising, but you can buy biotech stocks at rock-bottom levels

    Consider Gilead Sciences (GILD) and Celgene (CELG) for example. At recent prices of $70 and $75, they traded at market values that aren’t too far above the value of their operating businesses, according to discounted cash flow analysis by Jefferies biotech analyst Michael Yee and his team. Then add if they fall back to their “free pipeline” stock prices.

  • An expensive new medication is finally available for her rare disease — but she’s been fighting for two years to get it
    MarketWatch27 days ago

    An expensive new medication is finally available for her rare disease — but she’s been fighting for two years to get it

    More and more rare-disease medications have been approved in recent years, but a tangle of complications can keep promising but expensive therapies out of reach for patients.

  • See what the IHS Markit Score report has to say about Biogen Inc.
    Markit27 days ago

    See what the IHS Markit Score report has to say about Biogen Inc.

    Biogen Inc NASDAQ/NGS:BIIB

  • 5 Pharma Stocks to Stay Away From
    InvestorPlace28 days ago

    5 Pharma Stocks to Stay Away From

    Pharma stocks can serve as a profitable addition to investment portfolios. With 10,000 baby boomers aging into Medicare every day, and a Medicare Part D drug plan to subsidize the cost, demographics and government subsidies has created a virtuous cycle for healthcare stocks. As a result, some have seen price levels that its profits (assuming they exist) cannot sustain. Additionally, biotech stocks are inherently risky due to the process of drug development and approval.

  • Ionis Pharmaceuticals Collects Royalties -- and Spends It All
    Motley Fool28 days ago

    Ionis Pharmaceuticals Collects Royalties -- and Spends It All

    With $2 billion in the bank, the biotech can afford to invest in the future.